S
Shots:
- HanchorBio entered into an out-licensing agreement with Shanghai Henlius Biotech and granted exclusive rights to develop and commercialize HCB101 in Greater China, Southeast Asia, and MENA
- Under the terms and agreement, HanchorBio will receive $10M upfront and up to $192M in development and regulatory milestones, plus tiered royalties
- Henlius will also oversee development, production, and commercialization within the licensed regions, while HanchorBio maintains full rights in all other areas
Ref: PRNewswire | Image: HanchorBio&Henlius | Press Release
Related News:- UCB Reports the P-III Data of Fenfluramine in CDKL5 Deficiency Disorder (CDD) Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
